A plasma PD-L1 assay could overcome these tissue limitations and would also be able to assess dynamic changes of PD-L1 expression with treatment, recurrence, and upon progression guiding immune treatment decisions across the cancer treatment spectrum. The gene discussed is CD274; the disease is cancer.